Date:12/14/2011

oducts domestically and internationally, clinical and regulatory developments (domestic or foreign) involving current and future products, sales growth of recently launched products, competition from other products (domestic or foreign) and difficulties or delays in manufacturing our products. In addition, sales of our products are affected by reimbursement policies imposed by third-party payers, including governments, private insurance plans and managed care providers and may be affected by regulatory, clinical and guideline developments and domestic and international trends toward managed care and health care cost containment as well as U.S. legislation affecting pharmaceutical pricing and reimbursement. Government and others' regulations and reimbursement policies may affect the development, usage and pricing of our products. Furthermore, our research, testing, pricing, marketing and other operations are subject to extensive regulation by domestic and foreign government regulatory authorities. We, or others, could identify safety, side effects or manufacturing problems with our products after they are on the market. Our business may be impacted by government investigations, litigation and product liability claims. Further, while we routinely obtain patents for our products and technology, the protection offered by our patents and patent applications may be challenged, invalidated or circumvented by our competitors. We depend on third parties for a significant portion of our manufacturing capacity for the supply of certain of our current and future products and limits on supply may constrain sales of certain of our current products and product candidate development. In addition, we compete with other companies with respect to some of our marketed products as well as for the discovery and development of new products. Discovery or identification of new product candidates cannot be guaranteed and movement from concept to product is uncertain; consequently, there can
'/>"/>

SOURCE Amgen Copyright©2010 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3
Related medicine technology :

1. Amgen Announces Preliminary Results of Its Tender Offer
2. AMG 277 Discriminates Against S1P3 Receptor by 50-fold. S1P1 Lead Compounds Will Be Offered for Sale at a December 8, 2011 Sealed Bid Sale. Assets Generated by Epix Pharmaceuticals, Inc. and Amgen.
3. Amgen Statement on European Investor Visit
4. S1P1 Lead Compounds, Assets Generated by Epix Pharmaceuticals, Inc. and Amgen, Will Be Offered for Sale at a December 8, 2011 Sealed Bid Sale. Target Rationale for S1P1 Agonists Explained.
5. Back-Up Compounds and S1P1 Lead Compounds, Assets Generated by Epix Pharmaceuticals, Inc. and Amgen, Will Be Offered for Sale at a December 8, 2011 Sealed Bid Sale
6. Amgen Announces Webcast of 2011 Third Quarter Financial Results
7. Amgen Highlights Data to be Presented at 2011 European Multidisciplinary Cancer Congress
8. Amgen to Present at the Bank of America Merrill Lynch Global Healthcare Conference
9. Amgen to Present at the Morgan Stanley Global Healthcare Conference
10. Amgen to Present at the Baird Healthcare Conference
11. Amgen to Present at the Stifel Nicolaus Healthcare Conference